Please use this identifier to cite or link to this item:
Title: Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream.
Austin Authors: Goh, Michelle S Y
Affiliation: Department of Dermatology, Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 1-Aug-2006
Publication information: The Australasian Journal of Dermatology; 47(3): 186-8
Abstract: Squamous cell carcinoma in situ has the potential to progress to invasive squamous cell carcinoma. This report presents two cases of punch biopsy-proven squamous cell carcinoma in situ, treated with once-daily application of 5% imiquimod cream for 6 weeks. Both patients developed moderate local inflammatory reactions during treatment. The first patient demonstrated clinical clearance of the scalp lesion after treatment. Two months later, he re-presented with a subcutaneous nodule at the same site. Histology was consistent with recurrent squamous cell carcinoma. Five months following excision of the recurrent tumour, he presented with metastatic squamous cell carcinoma to a cervical lymph node. The second patient had low-grade chronic lymphocytic leukaemia and presented with squamous cell carcinoma in situ of the leg that failed to clear clinically after treatment with imiquimod. He presented 4 months later with a focus of invasive squamous cell carcinoma within the lesion.
Gov't Doc #: 16867000
DOI: 10.1111/j.1440-0960.2006.00269.x
Journal: The Australasian journal of dermatology
Type: Journal Article
Subjects: Administration, Topical
Aged, 80 and over
Aminoquinolines.administration & dosage
Antineoplastic Agents.administration & dosage
Carcinoma in Situ.diagnosis.drug therapy
Carcinoma, Squamous Cell.diagnosis.drug
Disease Progression
Head and Neck Neoplasms.diagnosis.drug
Lymph Node Excision
Lymphatic Metastasis
Middle Aged
Neoplasms, Second
Skin Neoplasms.diagnosis.drug
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 3, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.